{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:15:36Z","timestamp":1794575736735,"version":"4.9.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>\n                    This study examined the dose-response characteristics of aprocitentan, a dual endothelin A\/endothelin B receptor antagonist, in patients with essential hypertension. In a randomized, double-blind, parallel study design, eligible patients with a sitting diastolic blood pressure (BP) of 90\u2013109 mm Hg received aprocitentan 5, 10, 25, or 50 mg, placebo, or lisinopril 20 mg as a positive control once daily for 8 weeks. Multiple automated office BP readings were obtained with patients resting unattended (unattended automated office BP) at baseline, weeks 2, 4, and 8. Ambulatory BP was monitored for 24 hours at baseline and week 8. After a single-blind placebo run-in period, 490 eligible patients were randomized to the double-blind phase, with 409 patients completing 8 weeks of therapy per protocol. Aprocitentan 10, 25, and 50 mg decreased sitting systolic\/diastolic unattended automated office BP from baseline to week 8 (placebo-corrected decreases: 7.05\/4.93, 9.90\/6.99, and 7.58\/4.95 mm Hg, respectively,\n                    <jats:italic>P<\/jats:italic>\n                    \u22640.014 versus placebo), compared with an unattended automated office BP reduction of 4.84\/3.81 mm\u2009Hg with lisinopril 20 mg. For patients with valid ambulatory BP, aprocitentan 10, 25, and 50 mg significantly decreased placebo-corrected 24-hour BP by 3.99\/4.04, 4.83\/5.89, and 3.67\/4.45 mm Hg, respectively. Incidence of adverse events was similar in the aprocitentan groups (22.0%\u201340.2%) and the placebo group (36.6%). Aprocitentan produced dose-dependent decreases in hemoglobin, hematocrit, albumin, and uric acid, an increase in estimated plasma volume, but no change in weight versus placebo. These findings support further investigation of aprocitentan at doses of 10 to 25 mg in hypertension.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Registration\u2014<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique identifier: NCT02603809.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.119.14504","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T05:00:20Z","timestamp":1581915620000},"page":"956-965","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":92,"title":["Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension"],"prefix":"10.1161","volume":"75","author":[{"given":"Pierre","family":"Verweij","sequence":"first","affiliation":[{"name":"From Idorsia Pharmaceuticals, Ltd, Allschwil, Switzerland (P.V., P.D., B.F., M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Danaietash","sequence":"additional","affiliation":[{"name":"From Idorsia Pharmaceuticals, Ltd, Allschwil, Switzerland (P.V., P.D., B.F., M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Flamion","sequence":"additional","affiliation":[{"name":"From Idorsia Pharmaceuticals, Ltd, Allschwil, Switzerland (P.V., P.D., B.F., M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"M\u00e9nard","sequence":"additional","affiliation":[{"name":"Clinical Investigation Centre, Inserm \/Assistance Publique, H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges Pompidou (HEGP), Paris and Universit\u00e9 Paris-Descartes, France (J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bellet","sequence":"additional","affiliation":[{"name":"From Idorsia Pharmaceuticals, Ltd, Allschwil, Switzerland (P.V., P.D., B.F., M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_4_3_2","unstructured":"FDA. Hypertension: Conducting studies of drugs to treat patients on a background of multiple antihypertensive drugs guidance for industry. 2018. Available at:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hypertension-conducting-studies-drugs-treat-patients-background-multiple-antihypertensive-drugs. Accessed July 16 2019."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/332411a0"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20100222"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(01)02074-x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.253864"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803193381202"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61500-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.156976"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026611313020003"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009060593"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S199051"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12874"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.214106"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.234930"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03521.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00344.x"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6052"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011426432"},{"key":"e_1_3_4_21_2","unstructured":"EMA. Qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of phase II dose finding studies under model uncertainty. 2014. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-analysis-phase II_en.pdf. Accessed July 16 2019."},{"key":"e_1_3_4_22_2","unstructured":"FDA. Qualification of the MCP-Mod procedure. 2015. Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/UCM508702.pdf. Accessed July 16 2019."},{"key":"e_1_3_4_23_2","unstructured":"Bornkamp B Pinheiro J Bretz F. Dosefinding: Planning and analyzing dose finding experiments. 2018. Available at: https:\/\/cran.r-project.org\/web\/packages\/DoseFinding. Accessed July 16 2019."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02148"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI102501"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080117"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02616.x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.141879"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000087"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6551"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.06.003"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu467"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(94)00250-F"},{"key":"e_1_3_4_34_2","first-page":"7","article-title":"The value of 24-h blood pressure monitoring to assess the efficacy of antihypertensive drug treatment.","volume":"4","author":"O\u2019Brien E","year":"2011","unstructured":"O\u2019Brien, E. The value of 24-h blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Topics Hypertens. 2011;4:7\u201323.","journal-title":"Hot Topics Hypertens"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00722-4"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2012.07.034"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350180116018"},{"key":"e_1_3_4_38_2","unstructured":"EMA. Report from dose finding workshop december 2014. 2015. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/report\/report-european-medicines-agency\/european-federation-pharmaceutical-industries-associations-workshop-importance-dose-finding-dose_en.pdf. Accessed July 16 2019."},{"key":"e_1_3_4_39_2","first-page":"3049","volume-title":"In: Hypertension: Pathology, diagnosis and management","author":"Menard J","year":"1995","unstructured":"Menard, J, Bellet, M, Brunner, HR. Clinical development of antihypertensive drug. Laragh, JH, Brenner, BM, eds. In: Hypertension: Pathology, diagnosis and management. New York: Raven Press Limited; 1995:3049\u20133063."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.175646"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.01.853"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.119.14504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:22:42Z","timestamp":1715581362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.119.14504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.119.14504"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.119.14504","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737389891.793578608","asserted-by":"object"}]},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"2019-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}